Late last year, pharmaphorum caught up with Dr Karen Mullen, chief medical officer and VP of clinical & medical affairs at global drug development consultancy Boyds.
In recent years, pharma companies have invested heavily in their healthcare provider (HCP) portals, along with other digital solutions, to account for the reduction in face-to-face time bet
Leela Barham argues that the latest operational guidance for the NHS in England continues to illustrate a disconnect between the messages in big-ticket policy documents from the central gov
